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Summary
On basis of the present knowledge
and experience one can not select a
laboratory test that represents the
antithrombotic effect of heparin in a
patient. It is shown that on basis of
the existing evidence neither the
APTT, the anti-factor Xa test nor the
anti-factor IIa test can be accepted
as such. We suggest that the sur-
face under the thrombin generation
curve measured in clotting plasma is
potentially a more relevant para-
meter. This measurement would not
only apply to treatment with heparin
and heparinlike drugs of any kind but
also to oral anticoagulation.
Introduction
One of the main problems in develop-
ing a more efficient antithrombotic
treatment with heparins or related
drugs is to find the right laboratory
correlate to the antithrombotic action
in the patient. It would be extremely
useful if there would exist a test that
can be carried out on the plasma of a
patient, and the outcome of which
would correlate directly with the anti-
thrombotic potency obtained in the
patient. Such a test at this moment
does not exist, so it is necessary to
develop one.
Obviously it will be impossible to
select this test on basis of laboratory
research only, because antithrombotic
efficacy is a clinical concept and
cannot be translated a priori in
laboratory terms. What we can how-
ever do is judge the merits of the
available tests, select a plausible can-
didate and estimate its outcome in
patients in which, on basis of dose
finding studies, an efficient anti-
thrombotic therapy has been install-
ed. Then one can investigate whether
identical values are obtained in equal-
ly well anticoagulated patients. Even
though one cannot decide in favour of
a specific test on basis of laboratory
research only, it is already possible to
falsify existing claims on basis of our
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knowledge of the mechanism of ac-
tion of heparins and heparinlike drugs.
The prothrombin time e. g. would
obviously not do.
In this article we will explain why
we think that the current tests of
heparin acitivity do not suitably
reflect the effects of heparin and we
will propose the outlines of a new
one.
One general assumption underlies
the use of both our new suggestion
and the old tests viz: that antithrom-
botic drugs excert their action via
their influence on the clotting
mechanism. In view of the obser-
vation that the two main classes of
antithrombotics, i. e. oral anticoa-
gulants and heparins have nothing in
common but the sole fact fhat they
influence the amount of free throm-
bin formed in clotting plasma, this
assumption seems not unreasonable.
In view of the importance of
thrombin, we will start with a brief
reminder of the mechanism of throm-
bin generation and the influence of
antithrombotics on it.
1. The effect of
antithrombotics on
thrombin formation
On the basis of recent research it is
possible to sketch a plausible picture
of the course of events that leads to
blood coagulation and the ways in
which heparin and related drugs in-
hibit this process. Central to the com-
prehension of the inhibition is the
concept of positive feedback. This
mechanism as such is known for more
then 40 years (1, 2,3), yet its impor-
tance for the understanding of the
mode of action of heparins seems to
have been somewhat neglected. Feed-
back activation means that the pro-
duct of the reaction, i.e. thrombin ac-
tivates some of the reactions that lead
to its own formation. This implies
that in order for the mechanism of
coagulation to be operative, thrombin
has to be formed first by another
mechanism. We therefore cannot
speak of the mechanism of blood
coagulation. There must exist several
successive mechanisms of blood
coagulation. The best known is the
last one, i. e. the full-blown me-
chanism that is responsible for the
explosive thrombin formation occur-
ing after a certain lag phase. It should
always be kept in mind however that
in order to obtain the first traces of
thrombin, during the lag-phase a par-
tial mechanism must be operative that
allows enough thrombin to be formed
for the full mechanism to get going.
1. The ful l  coagulat ion
mechanism
Described in detail elsewhere (4), the
full coagulation mechanism will be
exposed here only in shorthand. Pro-
thrombin is activated by the pro-
thrombinase compleX that consists of
factor Xa and factor Va adsorbed
next to each other on a surface
constituted by negatively charged
phospholipids. Factor Xa is formed
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by the action of either the extrinsic-
or the intrinsic tenase complex. The
extrinsic tenase consists of a lipopro-
tein, called tissue factor (TF), to
which factor VII(a) is adsorbed. The
intrinsic tenase is a negatively charged
phospholipid surface to which factor
IXa and factor VIIIa are adsorbed.
The extrinsic tenase is not only
capable of activating factor X but can
also activate factor IX. It can thus
contribute to the formation of intrin-
sic tenase. In this way a reinforcement
loop is formed: the Josso loop.
The alternative way to activate fac-
tor IX is via the contact activation
pathway; that is by factor XIa,
resulting from the interaction of a
negatively charged (glass-, kaolin-,
ellagic acid) surface with the factors
XII, XI, prekallikrein and high
molecular weight kininogen. The
physiologic importance of this
pathway remains questionable. It is
however the mechanism operative in
the activated partial thromboplastin
time (APTT).
2. Partial coagulation
mechanisms
The full coagulation mechanism, that
serves to produce the bulk of throm-
bin in clotting plasma and
presumably at the sites of haemosta-
sis and thrombosis cannot be
operative from zero time on, for the
very simple reason that blood im-
mediately after the reaction has been
triggered does not contain three of its
main reactants to wit: Factor VIIIa.
factor Va and the bulk of pro-
coagulant phospholipids. These are
produced only after the first traces of
thrombin have been formed. In order
to start full-blown thrombin forma-
tion, incomp lete, partial mechanisms
have to form small amounts of throm-
bin first.
One of the possible incomplete
mechanisms and for the purpose of
this presentation the only one to be
discussed, is the one that might be
operative in blood that comes into
contact with a damaged cell (Fig. 1).
Fig 1. The Lag-Time-Phase
There, tissue thromboplastin will com-
bine with factor VII and form an -
inefficient extrinsic tenase. This
forms slowly some factor IXa and
some factor Xa. These factors ac-
tivate factor VII so that the extrinsic
tenase becomes more efficient. The
factor IXa may form some more fac-
tor Xa if small amounts of pro-
coagulant phospholipid escape from
wounded cells. With the same
phospholipid factor Xa can activate
some prothrombin and in this way
give rise the generation of small
amounts of thrombin. This thrombin
then can activate: a) factor VIII,
b) factor V and c) platelets. In this
way the factors VIIIa, Va and pro-
coagulant phospholipids become
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available and full thrombin formation
sets in (Fig. 2). The clotting process
thus can be thought to exist of three
separate phases: a) partial triggering
mechanism(s), b) thrombin mediated
feedback and c) full blown thrombin
formation.
Fig.2 The Feedback Phase
3. Clotting times and thrombin
formation
Clotting invariably occurs when a
level of 10-20nM of thrombin is
attained in blood or plasma. That is
shortly after the onset of the full
coagulation mechanism. The clotting
time therefore measures the lag-time
of thrombin formation during which
mainly partial triggering mechanism
and thrombin mediated feedback are
operative (phases a and b). Conse-
quently measuring the influence of a
drug such as heparin on a clotting
time essentially measures its effect on
a partial coagulation mechanism and
not on the ful l  mechanism.
A simple clinical fact illustrates that
the lag time of thrombin formation -
and therefore the clotting time - can-
not be the only parameter from which
to judge antithrombotic action. A pa-
tient with a congenital antithrombin III
deficiency of 5090 will have an impor-
tant thrombotic tendency. Yet none
of the possible variants of the clotting
time will shown significant prolonga-
tion. The parameter that ls influenced
is the amount of thrombin formed
during the action of the full coagula-
tion mechanism. The idea that the
amount of thrombin formed in a
patient is related to his thrombotic
tendency is supported by more clinical
observations. The fact that all effi-
cient antithrombotic therapies in-
fluence the amount of thrombin pro-
duced but do not necessarily affect
the lag time is the most important
one. Low-molecular-weight (LMW)
heparins for instance are efficient an-
tithrombotics and yet hardly in-
fluence clotting times. Dermatan
sulfate affects clotting times even less.
Mind that we do not say that the an-
tithrombotic potency may not, under
circumstances, be related to (a varia-
tion of) the clotting time. Oral an-
ticoagulant treatment and the pro-
thrombin time (P. T.) show that this is
not true. The fact however that effi-
cient antithrombotics exist that do not
influence a clotting time, whereas
these drugs all influence the amount
of thrombin formed is the crucial
observation.
2. Heparin measurement
Heparin, both in its unfractionated
and in its low molecular weight
forms. can be demonstrated on basis
of one or more of the effects caused
by its potentiation of antithrombin III
(AT III). There are three main forms
of test: the activated partial throm-
boplastin time (APTT), the anti-factor
Enzyme Substrate Product
l la :  !  + Va
V l l l  +  V l l l a
platelets - procoag. pL
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IIa (anti-thrombin) test and the anti-
factor Xa test. The prolongation of
the thrombin time is a form of an-
tithrombin test. The Heptest is a
hybrid form of an APTT and an anti-
Xa test.
The APTT comes nearest to an
overall test of the coagulation
mechanism. It measures essentially
the influence of heparin on the par-
tial clotting mechanisms that are
operative when thrombin formation is
triggered via contact activation. We
have demonstrated that the essential
point is, that heparin lowers the
available thrombin concentrations
during the lag phase so that factor-
VIII activation is retarded (5). Factor-
IX activation is normal, however.
Physiologically factors VIIIa and IXa
form intrinsic tenase that is practi-
cally immune to the action of AT
Ill-heparin. When no factor VIIIa
becomes available the free factor IXa
that is generated by contact activation
is vulnerable to the attack by AT III-
heparin. Therefore the capacity to
form complete tenase will be retard-
ed. Consequently the formation of
factor Xa will be retarded and
diminished. If factor Xa is formed
then it may be attacked in its turn
when, due to the low ambient concen-
tration of thrombin, no factor Va is
present. For unknown reasons the lat-
ter mechanism does not seem to be
rate limiting. Else not only the contact
activated APTT but also the trom-
boplastin induced PT would be
heparin sensitive.
Both the anti-factor IIa and the anti-
factor-Xa test measure properties that,
in a well designed test, are functions
of the heparin concentration only.
Different functions though. It is com-
mon knowledge that, for an ATIII
molecule to be activated towards factor
Xa, it is necessary and sufficient that
its heparin binding site binds to a
heparin. A pentasaccharide of defin-
ed composition is the minimal struc-
ture required (6). Larger heparins
may be more efficient because of a
more efficient interaction with AT III
but not because of binding to factor
Xa. The anti-Xa level therefore in-
dicates the number and efficacy of
the ATIII binding sites in a heparin.
For efficient thrombin inhibition
however, it is necessary that thrombin
also binds to the heparin. According
to the "sliding hypothesis" binding of
thrombin and ATIII to the same
heparin molecule enhances the in-
activation of thrombin importantly
(7-10).  For this to happen i t  is
necessary that the heparin is signifi-
cantly larger then its ATIII binding
site. Anti-factor IIa based determina-
tions of heparin therefore measure
that subfraction of ATIII binding
sites that is embedded in an efficient,
larger molecular weight heparin.
3. The laboratory
correlate to heparin
eff icacy
As explained above the three tests that
are currently in use for assessing
heparin in a patient plasma measure
quite different propefiies. It has not
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been proven and it is not to be ex-
pected that one of these properties
directly reflects the therapeutic ef-
ficacy of heparin. As exposed, the
APTT is sensitive to the influence
of heparin on the partial clotting
mechanism, operative during the lag
time of thrombin formation. This will
not necessarily correlate with the in-
hibition of the bulk of thrombin for-
mation by the full mechanism. The
anti-factor Xa action is the property
most frequently used for assessing
heparin levels in patients, were it only
because it is easily measurable with
the aid of a commercialized kit and
because it changes significantly after
injection of LMW heparin. It has
been claimed that its results correlate
with the therapeutic efficacy (11- l8).
Others however have not found this
relationship (19-26). Dose finding
studies with different commer cialized
LMW heparins lead to doses that do
not differ more then 10090 as to the
anti-Xa levels obtained. This is readi-
ly explained by the similarity of these
products. The correlation between ef-
ficient dosis and anti-factor Xa level
quickly disappears when less similar
preparations are investigated. Unfrac-
tionated heparin causes low anti-
factor Xa levels and the specific pen-
tasaccharide has to be administrated
(in animals) in doses causing anti-
factor Xa levels that are 10 x higher
then that of the other LMW heparins
(26). We therefore tend to accept
rather the negative evidence and ques-
tion the value of anti-factor Xa mea-
surements.
More important still is the observa-
tion that both UFH and LMW
heparin do not influence the thrombin
generated in clotting plasma to any
significantly further extend then can
be explained by their antithrombin
properties (5). In other words, the
anti-factor Xa capacity of both UFH
and most LMW heparins does not or
hardly influence the generation of
thrombin in plasma, at least in the ex-
trinsic system. This is explained by the
fact that factor Xa is produced in
tremendous excess and therefore very
difficultly will become rate limiting.
As we have discussed above, in the in-
trinsic system the situation is dif-
ferent. There the fast disappearance
of thrombin brought about by
heparin during the lag phase causes a
retardation of factor VIII activation
and thus an increase of the lag phase.
During this time heparin-ATIII can
attack factor IXa that is formed nor-
mally. When finally factor VIIIa is
formed it finds only small amounts of
factor IXa left to form intrinsic tenase
activity. This activity is consequently
diminished. In mechanisms were fac-
tor VIII plays a role the influence of
a heparin on factor IXa is a conse-
quence of antithrombin action
because of the fact that it is the lack
of thrombin that causes no factor
VIIIa to be available to protect factor
IXa. So anti-factor IIa and anti-
factor Xa effects will tend to reinforce
each-other. An effect of anti-factor
Xa activity has as yet not been
demonstrated.
It is anyhow clear that anti-factor
Xa activity cannot be the physiolo-
:
I
I
)
The Thrombin Potential 95
gical correlate to the antithrombotic
action of heparin. Antifactor IIa
remains a better candidate but must
be discarded on basis of the anti-fac-
tor IXa anti-factor IIa synergy
described above. Whether a labora-
tory test is a good correlate to an-
tithrombotic action can only be decid-
ed on basis of correlations in clinical
trials. Yet we think that at this mo-
ment it is more likely then not that the
amount of thrombin formed by a
clotting plasma under the influence of
heparin has something to do with the
antithrombotic action. Measuring
thrombin production is a much more
direct way of measuring the effect of
heparin and once one accepts that the
antithrombotic effect of heparin, like
that of oral anticoagulation, is due to
its effect on thrombin (formation
and/or breakdown), a supposition
also tacidly at the basis of the current
tests, it is a very acceptable candidate
for the laboratory correlate.
4, The thrombin potential
"After all it is more like cooking then
like anything else" goes the famous
saying of Rosemary Biggs, speaking
of coagulation research. Indeed, in
the light of what we know now, we
can only admire the ways in which the
clotting mechanism was forced to
render its secrets by measuring clot-
ting times in clever combinations of
clotting mixtures. These results led to
a correct overall scheme of coagula-
tion. After the clotting age came the
age of biochemistry. All factors were
purified and the enzymology of their
interactions was studied in meticulous
detail. What remains to be completed
is a study in physiological chemistry.
Experiments on the isolated organ
called "blood" are to reveal what
reactions that are biochemically pos-
sible are important physiologically.
Blood includes plasma and blood cells
of all sorts. One might also include
the endothelium and the subendothe-
lium. Modern hemostasis research
more and more reckons with these
formed elements. It is strange to
realize how far clinical biology lags
behind the state of the art in
physiological chemistry. Either it
resources to the APTT, a direct
descendant of "first generation" clot-
ting tests or it measures single proper-
ties like anti-factor IIa or anti-factor
Xa capacity without taking into ac-
count the obvious fact that the con-
centration of only one effector in a
strongly non-linear network like
thrombin generation will hardly ac-
count for the effects observed.
We therefore tried to find a
parameter that reflects as precisely as
possible the processes that are in-
fluenced by any type of anticoagulant
drug. I. e. a procedure beyond the
scope of the determination of an
individual factor or a clotting time.
We think we have found this procedure
in the thrombin generation assay
(T.G.A.).  In a ser ies of studies we
have confirmed that indeed the
.T. G. A. is influenced by all classes
of confirmed antithrombotic drugs
(5,28-31).  We have shown that oral
anticoagulation as well as heparin and
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heparinlike drugs influence this test,
be it by completely different mecha-
nisms. We also showed how, by ma-
thematical dissection of the curve, it
was possible to discern between the
effects of a drug on thrombin break-
down or on prothrombin conversion
(32).
To obtain a precise thrombin
generation curve is a tedious pro-
cedure not applicable to routine use in
the clinical laboratory. We therefore
set out to find a simple test that
directly assesses one of the critical
parameters of this curve. Because
thrombin is an enzyme one can
assume that a high concentration act-
ing during a short time will have the
same effect as a low concentration
acting during a long time. The con-
centration-time integral, i. e. the sur-
face under the curve may therefore
conceivably be an interesting parameter
to measure. In fact it is a timeho-
noured procedure to measure this sur-
face to render the result of a T. G. A.
when it serves for two-stage pro-
thrombin estimation (3). This surface
we will henceforward call the throm-
bin potential.
For the purpose of this article we
determined the thrombinpotential by
calculation from thrombin generation
curves. Because the thrombin poten-
tial is a surface in the concentration-
time plane of thrombin, its dimension
is concentration multiplied by time.
We calculated it as as nanomoles per
liter times minutes. The normal value
was 487 -f 2l nM.min (n : 12).
5. The influence of
antithrombotics on the
thrombin potential
Figure 3 shows a series of thrombin
generation curves, obtained as de-
control
0 .01  U/ml  UFH
0.02 U/ml UFH
0.03 Uiml UFH
0.04 U/ml UFH
0.05 U/ml UFH
Fig. 3. The inf luence of UFH on thrombin generation tr iggered via the extr insic
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scribed in ref. 5 and corrected for the
contribution ofthe amidolytically ac-
tive c,r-macroglobulin-thrombin com-
plex. From Figure 4 it is seen that the
thrombin-potential follows closely the
thrombin-peak. This thrombin- peak
is the value that we used until now to
determine the overall effect of an an-
tithrombotic drug. Its value is strong-
ly linked to the thrombin-potential.
The reasons to prefer the thrombin-
potential are both theoretical and
practical. On a theoretical basis one
can, as explained above, assume that
much thrombin during a relatively
short time will have the same effect as
less thrombin during a proportionally
shorter time. It has been proven for
the action of thrombin on fibrinogen
that the product of thrombin concen-
tration and clotting time is constant
(33). This means that at least for that
experimental system our assumption
is true. It seems not far fetched to
extend it to other actions of thrombin.
Also a thrombin potential can be
measured with more precision than a
thrombin peak value. From discon-
tinuously measured curves, as in
Figure 3 one can make a reasonably
exact guess of the peak values, but
this needs frequent sampling and the
possibility remains that the actual
peak of the curve is missed by the ex-
perimental points. For the surface
under the curve however, all measur-
ing points are used and missing the
peak has no serious consequences.
Also, the experimental error with
which the peak is measured is equal to
- or larger then - the error of an in-
dividual point. The error of all the
measuring points used in determining
the surface will equal out as in deter-
mining a mean i. e. the error will be
roughly equal to the experimental er-
Fig.4. The relat ion between thrombin potential and thrombin peak in heparinized
Dlasma
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ror of a single point devided by the
square root of the number of points.
The third and main point however,
is that we have good hope to design a
method that in one simple chromo-
genic test measures the thrombin
potential. If indeed this test comes out
as we hope it does then it will be pos-
sible to follow the thrombin integral
in the clinical laboratory as a routine
procedure.
As a prelude we measured the in-
fluence of different low molecular
weight heparins on the thrombin in-
tegral, the thrombin peak and the
prothrombinase peak (Figs. 5-6 and
7). We also compared the influence of
three different LMW heparins on the
thrombin potential (Fig. 6). In order
to show that the thrombin integral
indeed varies with the anticoagulant
level in patients we compared the
thrombin potential and the prothrom-
bin level in a series of 23 anti-
coagulated patients and 4 normal
subjects (Fig. 8).
References
1. Ware AG, Seegers WH. Serum Ac-globulin:
formation from plasma Ac-globulin: role in
blood coagulation; partial purification; proper-
ties and quantitative determination. Am J
Physiol 1948;152:567
2. Alexander B, Goldstein R, Landrvehr G. The
prothrombin conversion accelerator of serum
(S.P.C.A.): in partial purification and its
properties compared with serum AC-globulin.
J Clin Invest 1950; 29: 881
3. Biggs R, Macfarlane RG. In: Human Blood
Coagulation and its Disorders. Oxford:
Blackwell, 1953
4. ZwaaI RFA, Hemker HC. New Comprehensive
Biochemistry, Vol. 13: Blood Coagulation.
Amsterdam: Elsevier, 1986
5. B6guin S, Lindhout T, Hemker HC. The mode
of action of heparin in plasma. Thromb
Haemost 1988: 60: 457 -462
Fig. 5. Thrombin peak inhibit ion
a_a
Enoxaparine@
a- - - -a
Fraxiparine@
4 . .  . . . a
cY 222
75
;R 50
z.
8 2 5
-
z
0
-25
2
L.M.w.H. ( t"g/^t )
*r*-a
*.K/
/
The Thrombin Potential gg
1 0 0
| e 5 0
z
F
E Z J
-
z
-25
2
L.M.W.H. ( ps/mt )
Fig. 6. Prothrombinase peak ihhibition
Fig.7. Thrombin potential inhibition
H
UFH
H
Enoxaparineo
o----o
Fraxiparineo
o. . . . . .o
cY 222
H
Enoxaparine@
o----o
Fraxiparineo
oo
cY222
DS
z
o
T.
z
75
50
25
0
-25
2
L.M.W.H. ( pg/mt )
- a
- - ) ) . - '
o- ^z'
a'o
//
a t
t.2'
o '
o
100 H.C. Hemker,  S.  Wielders,  S.  869uin
cq
c
.F
c()
o(L
c
:E
o
c
F
400
300
200
1 0 0
0
25 50 75  100
P r o t h r o m b i n l e v e t  ( % )
o
o o
o
o O 1
o
o
o
Fig. 8. The thrombin potential compared to the prothrombin level in anticoaou-
lated oatients
6. Choay J, Petitou M, Lormeau JC, Sinay p,
Casu BJ, Gatti G. Structure activity relation_
ship in heparin; a synthetic pentasaccharide
with high affinity for antithrombin III and
eliciting high anti factor Xa activity. Biochem
Biophys Res Commun 1983; 116: 492-gg
7. Holmer E, Kurachi K, Sciderstrcim G. The
molecular weight dependence of the rate enhan_
cing effect of heparin on the inhibition of
thrombin, factor Xa, factor IXa, factor XIa.
factor XIIa and kallikrein by antithrombin.
Biochem J 1981; 193:  295
8. Griffith MJ. Kinetic of the heparin-enhanced
antithrombin III, thrombin reaction. Evidence
for a template model for the mechanism of ac-
tion of heparin. J Biol Chem i982; 157:7360
9. Lane DA, MacGregor IR, Michalski R, Kakkar
W. Anticoagulant activities of four unfrac_
tionated and fractionated heparins. Thromb
Res 1978: 12:  57
10. Petitou M. Synthetic heparin fragments: new
and efficient tools for the study of heparin and
its interactions. Nouv Rev Frang d'H6matol
7984: 26: 221
11. Tew CJ, Lane DA, Thompson E, Ireland H.
Curtis JR. Relationship between ex vivo anti-
proteinase (factor Xa and thrombin) assays and
in vivo anticoagulant effect of very low
molecular weight heparin, Cy 222. Br J
Haematol 1988: 70: 335-40
12. Albada J, Nieuwenhuis HK, Sixma JJ. Treat-
ment of acute venous thromboembolism with
low molecular weight heparin (Fragmin): results
of a double blind study. Thromb Haemost
1989; (in press)
13. Levine MN, Planes A, Hirsh J, Goodyear M,
Vochelle N, Gent M. The relationship between
anti-factor Xa level and clinical outcome in pa-
tients receiving enoxaparine low molecular
weight heparin to prevent deep vein thrombosis
after hip replacement. Thromb Haemost lggg;
14. Dechavanne M, Ville D, Berruyer M, Trepo F,
Clermont N, Lerat JL, Moyen B, Fischer Lp,
Kher A, Barbier P. Randomized trial of a low-
molecular-weight heparin (Kabi 2165) versus
adjusted-dose subcutaneous standard heparin in
the prophylaxis of deep-vein thrombosis after
elective hip surgery. Haemostasis 1989: l: 5 - 12
15. Kakkar VV, Djazaeri B, Fok J, Fletcher M.
Scully MF, Westwick J. Low molecular weight
heparin and prevention of postoperative deep
vein thrombosis. Br Med J 1982:284: 375-79
16. Cadroy Y, Harker LA, Hanson SR. Inhibition
of platelet dependent thrombosis by LMWH
(CY 222). Comparison with standard heparin.
J Clin Med (in press)
17. Dieval J, Morinidre P, Bayrou B, Roussel B.
Fournier A, Delobel J. Dose-finding study of
the low molecular weight heparin Cy 216 in
chronic haemodialysis. In: Fraxiparine. First
The Thrombin Potential  101
International Symposium. Breddin K, Fareed J,
Samama M (eds). Stuttgart, New york: Schat_
tauer, 1989; pp 169-76
18. Ireland H, Lane DA, Flynn A. Low molecular
weight heparin in haemodialysis for chronic
renal failure. A dose finding study of Cy 222.
Thromb Haemost 1988; 59: 24O-47
19. Aiach M, Sie P. Surveillance biologique des
traitements par les h6parines de bas poids
mol6culaire. Ann Biol Clin 1988; 46: 1.l5-7g
20. Vairel EG, Brouty-Boye H, Toulemonde F.
Heparin and a low molecular weight fraction
enhances thrombolysis and by this pathway ex_
ercices a protective effect against thrombosis.
Thromb Res 1983: 30:219-24
21. Doutremepuich C, Bousquet F, Toulemonde F.
Are molecular weight and anti-Xa activity suffi_
cient to predict the antithrombotic power of
heparin fractions? Thromb Res 19g6: 44:
709 - t2
22. Ockelfofi PA, Carter CJ, Mitchell L. Discor-
dance between the anti-Xa activity and the anti_
thrombotic activity of an ultra-low molecular
weight heparin fraction. Thromb Res l9g2; 29:
401 - 09
23. Bender N, Kirchmaier CM, Weichert W. Effect
of different low molecular weight heparin on
the bleeding time, anti-Xa plasma levels and
laser induced thrombus formation in rats after
adjustment of the doses according to their anti-
Xa activity. Haemostasis 1986; 5: 137 (Abstr
I  88)
24. Doutremepuich C, Castrioto T, de Seze O.
What is the best plasmatic activity which could
be correlated with the antithrombotic effect of
heparin and a low molecular weight heparin
fragment? Thromb Res 1987; 48:245-51
25. Hobbelen PM, Vogel GMT, princen AWM.
Time course of the effects of some heparinoids
on bleeding and the interactions of these
substances with factor Xa and thrombin in rats.
Thromb Res 1986; (Suppl VI): l18, Abstr 233
26. Levine MN, Hirsh J. Clinical use of low
molecular weight heparins and heparinoids.
Semin Thromb Haemost 1988; 14: 116-25
27. Walenga JM, Fareed J, petitou M, Samama M.
Lormeau JC, Choay J. Intravenous antithrom-
botic activity of a synthetic heparin pentasac_
charide in a human serum induced stasis throm-
bosis model. Thromb Res 1986; 43:243-48
28. XIMA, B6guin S, Hemker HC. Importance of
factor-IX dependent prothrombinase formation
- The Josso Pathway - in clotting plasma.
Haemostasis 1989; 19: 301 - 08
29. B6guin S, Mardiguian J, Lindhout T, Hemker
HC. The mode of action of low molecular
weight heparin preparation (pKl0l69) and two
of its major components on thrombin genera-
tion in plasma. Thromb Haemost 19g9: 61:
J - J 4
30. B6guin S, Dol F, Hemker HC. Influence of lac-
tobionic acid on the kinetics thrombin in human
plasma. Semin Haematol 1989; (in press)
31. Hemker HC, B6guin S. The mode of action of
heparin and related drugs Semin Haematol
1989; (in press)
32. Hemker HC, Willems GM, B6guin S. A com-
puter assisted method to obtain the prothrom_
bin activation velocity in whole plasma indepen-
dent of thrombin decay process. Thromb
Haemost 1986; 56: 9 - ll7
33. Hemker HC, Kop JJM, Willems GM. Kinetic
aspects of the interaction of blood clotting en-
zymes. VIII. The relation between clotting time
and clotting velocity. Thromb Haemost 1979:
4 l : 309 -13
